Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer

Trial Profile

Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms REGO-ACT
  • Sponsors Bayer
  • Most Recent Events

    • 12 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 02 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 27 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top